Scholars Central

Review articlePublished 15 Jul 2016

Targeted therapy for high-risk endometrial carcinoma

Authors: Dana M Roque, Peter E Schwartz, Alessandro D Santin

Clinical Practice

Volume 9 · Issue 5 · Pages 539

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Type II endometrial cancers exhibit distinct histopathology, underlying pathogenesis and clinical behavior. These high-risk cancers are associated with an aggressive clinical course and a relatively poor prognosis that underscores the need for the development of novel rational therapeutic strategies that exploit their distinct underlying molecular pathway alterations. In this review, we describe the extent of disease burden and molecular characterization of type II endometrial cancers, summarize the historical development to support current standards of care and delineate the most recent preclinical and clinical advances in immunotherapy, cytotoxic agents and small-molecule inhibitors for this disease.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Practice.

All its articles

Article · 28 Mar 2025

Using

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Practice
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Dana M Roque”
  • BylineArticles whose byline prints “Peter E Schwartz”
  • BylineArticles whose byline prints “Alessandro D Santin”